Cargando…
EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically “healthy cells”. Objective:...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262165/ https://www.ncbi.nlm.nih.gov/pubmed/34257550 http://dx.doi.org/10.3389/pore.2021.598292 |
_version_ | 1783719136700923904 |
---|---|
author | Chalela, Roberto González-García, Jose Gregorio Khilzi, Karys Curull, Víctor Sánchez-Font, Albert Longarón, Raquel Rodrigo-Calvo, María Teresa Martín-Ontiyuelo, Clara Gea, Joaquim Bellosillo, Beatríz |
author_facet | Chalela, Roberto González-García, Jose Gregorio Khilzi, Karys Curull, Víctor Sánchez-Font, Albert Longarón, Raquel Rodrigo-Calvo, María Teresa Martín-Ontiyuelo, Clara Gea, Joaquim Bellosillo, Beatríz |
author_sort | Chalela, Roberto |
collection | PubMed |
description | The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically “healthy cells”. Objective: to demonstrate the presence of EGFR or KRAS mutations in non-tumoral lung cells in subjects with ADC and negative mutational status. Results: mutations in EGFR or KRAS oncogenes were identified in the normal lung in 9.7% of the subjects. Exon 21 substitution L858R in EGFR was detected in two cases while the exon 19 deletion E746-A750 in the EGFR, the G12C and G12D substitutions in the KRAS were detected once. One patient presented three different mutations in the normal lung parenchyma (EGFR_L858R, KRAS_G12C and KRAS_G12D). The negative-mutation status of the tumor and the mutations detected in the “normal lung” were confirmed using highly sensitive and specific TaqMan PCR (CAST-PCR). No differences were found in terms of progression, progression-free survival or overall survival during the 18 months follow-up. Conclusions: These results confirm the presence of driver mutations in the histologically normal lung parenchyma cells in the absence of mutations coexisting with the primary tumor. |
format | Online Article Text |
id | pubmed-8262165 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-82621652021-07-12 EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma Chalela, Roberto González-García, Jose Gregorio Khilzi, Karys Curull, Víctor Sánchez-Font, Albert Longarón, Raquel Rodrigo-Calvo, María Teresa Martín-Ontiyuelo, Clara Gea, Joaquim Bellosillo, Beatríz Pathol Oncol Res Society Journal Archive The acquisition of driver mutations in non-tumoral cells appears to be very important during the carcinogenesis of adenocarcinoma (ADC). Recent studies suggest that cancer-related mutations may not necessarily be present only in malignant cells, but also in histologically “healthy cells”. Objective: to demonstrate the presence of EGFR or KRAS mutations in non-tumoral lung cells in subjects with ADC and negative mutational status. Results: mutations in EGFR or KRAS oncogenes were identified in the normal lung in 9.7% of the subjects. Exon 21 substitution L858R in EGFR was detected in two cases while the exon 19 deletion E746-A750 in the EGFR, the G12C and G12D substitutions in the KRAS were detected once. One patient presented three different mutations in the normal lung parenchyma (EGFR_L858R, KRAS_G12C and KRAS_G12D). The negative-mutation status of the tumor and the mutations detected in the “normal lung” were confirmed using highly sensitive and specific TaqMan PCR (CAST-PCR). No differences were found in terms of progression, progression-free survival or overall survival during the 18 months follow-up. Conclusions: These results confirm the presence of driver mutations in the histologically normal lung parenchyma cells in the absence of mutations coexisting with the primary tumor. Frontiers Media S.A. 2021-03-24 /pmc/articles/PMC8262165/ /pubmed/34257550 http://dx.doi.org/10.3389/pore.2021.598292 Text en Copyright © 2021 Chalela, González-García, Khilzi, Curull, Sánchez-Font, Longarón, Rodrigo-Calvo, Martín-Ontiyuelo, Gea and Bellosillo. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Society Journal Archive Chalela, Roberto González-García, Jose Gregorio Khilzi, Karys Curull, Víctor Sánchez-Font, Albert Longarón, Raquel Rodrigo-Calvo, María Teresa Martín-Ontiyuelo, Clara Gea, Joaquim Bellosillo, Beatríz EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma |
title | EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma |
title_full | EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma |
title_fullStr | EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma |
title_full_unstemmed | EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma |
title_short | EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma |
title_sort | egfr and kras mutations in lung parenchyma of subjects with egfr/kras wild-type lung adenocarcinoma |
topic | Society Journal Archive |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262165/ https://www.ncbi.nlm.nih.gov/pubmed/34257550 http://dx.doi.org/10.3389/pore.2021.598292 |
work_keys_str_mv | AT chalelaroberto egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT gonzalezgarciajosegregorio egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT khilzikarys egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT curullvictor egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT sanchezfontalbert egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT longaronraquel egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT rodrigocalvomariateresa egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT martinontiyueloclara egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT geajoaquim egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma AT bellosillobeatriz egfrandkrasmutationsinlungparenchymaofsubjectswithegfrkraswildtypelungadenocarcinoma |